
ANA aircraft
15:59 JST, October 6, 2022
TOKYO (Jiji Press) — All Nippon Airways told its labor union on Wednesday of its plan to pay winter bonuses for the first time in three years.
The major Japanese airline will resume its winter bonus payments in response to a recovery in travel demand from a plunge due to the novel coronavirus pandemic, and also in a bid to ease concerns among its workers over rising prices.
Specifically, the company plans to provide winter bonuses worth two months’ salary in fiscal 2022.
In fiscal 2019, ANA paid summer and winter bonuses each equivalent to two months’ salary.
Following the pandemic-induced deterioration in the business environment, the company halved the summer bonus payments to one month’s salary in fiscal 2020, skipped winter bonus payments in fiscal 2020 and paid no bonuses throughout fiscal 2021.
In the current fiscal year, the company paid summer bonuses worth one month’s salary.
The company also proposed providing special allowances worth up to one month’s salary that would be paid separately from summer and winter bonuses based on earnings results at the end of the fiscal year.
Top Articles in Business
-
Nippon Life Insurance’s U.S. Arm Sues OpenAI Over Legal Assistance Provided by ChatGPT
-
Japan, U.S. Name 3 Inaugural Investment Projects; Reached Agreement After Considerable Difficulty
-
Japan’s Major Real Estate Firms Expanding Overseas Businesses to Secure Future Growth, Focusing on Europe, U.S., Asia
-
JR Tokai Breaks Ground on Yamanashi Maglev Station; Will Be Part of Linear Chuo Shinkansen Line from Tokyo to Nagoya
-
Transport Companies See Opportunity in Narita Expansion; Airlines, Railways Prepare to Meet Expected Growth in Demand
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

